Dr. William B. Pearse, MD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 11
- In the NPI registry since
- 2015
- Medicare patients seen, 2024
- 201
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2015Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
CA license 173950 · OR license MD227390 -
Hematology (Internal Medicine) Physician
OR license MD227390 -
Internal Medicine Physician
IL license 123456789
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- UC San Diego Health Hillcrest - Hillcrest Med Ctr San Diego, CA
- Providence Portland Medical Center Portland, OR
- Providence Milwaukie Hospital Milwaukie, OR
Medical groups
- Regents of the University of California (2,089 clinicians)
- Providence Health and Services Oregon (1,433 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 201
- Services billed
- 509
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 138 | 51 |
| Established patient office or other outpatient visit, 30-39 minutes | 88 | 69 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 48 | 20 |
| New patient office or other outpatient visit, 60-74 minutes | 40 | 40 |
| New patient office or other outpatient visit, 45-59 minutes | 33 | 33 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 30 | 30 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 24 | 16 |
| Advance care planning, first 30 minutes | 12 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Hydroxyurea Other prescribers in Portland, OR | 63 |
| Eliquis (apixaban) Other prescribers in Portland, OR | 52 |
| Acyclovir Other prescribers in Portland, OR | 39 |
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in Portland, OR | 29 |
| Ondansetron Odt (ondansetron) Other prescribers in Portland, OR | 26 |
| Calquence (acalabrutinib maleate) | 25 |
| Dexamethasone Other prescribers in Portland, OR | 22 |
| Imatinib Mesylate | 22 |
| Prochlorperazine Maleate Other prescribers in Portland, OR | 19 |
| Prednisone Other prescribers in Portland, OR | 16 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $37,780 in research payments for these studies, mostly to the institutions running them.
- Prospective, Open-Label, Single-Arm, Phase II Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL (ACRUE)
AstraZeneca UK Limited - A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.
Epizyme, Inc. · Active, not recruiting · NCT04224493
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.